|
See related Tarceva film-coated tab information |
|
|
|
Manufacturer |
Roche |
|
Distributor |
DKSH |
|
Contents |
Erlotinib HCl |
|
Indications |
Maintenance therapy in patients w/ locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not progressed on 1st-line chemotherapy. Locally advanced or metastatic NSCLC after failure of at least 1 prior chemotherapy regimen. In combination w/ gemcitabine as 1st-line treatment of locally advanced, unresectable or metastatic pancreatic cancer.
Click to view Tarceva detailed prescribing infomation |
|
Dosage |
NSCLC 150 mg once daily. Pancreatic cancer 100 mg once daily.
Click to view Tarceva detailed prescribing infomation |
|
Overdosage |
View Tarceva overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken on an empty stomach (Take on an empty stomach at least 1 hr before or 2 hr after meals.). |
|
Contraindications |
[Click for Tarceva detailed prescribing infomation] |
|
Special Precautions |
Interstitial lung disease associated w/ concomitant or prior chemotherapy, prior radiotherapy, preexisting parenchymal lung disease, metastatic lung disease or pulmonary infections. Discontinue in case of development of acute onset of new &/or progressive unexplained pulmonary symptoms eg dyspnea, cough & fever; severe or persistent diarrhea, nausea, anorexia or vomiting associated w/ dehydration; GI perforation. Smoking. Pregnancy & lactation. Patient <18 yr.
Click to view Tarceva detailed prescribing infomation |
|
Adverse Drug Reactions |
Rash, diarrhea, fatigue, dyspnea, cough, nausea, vomiting, stomatitis, abdominal pain, infections, conjunctivitis, keratoconjunctivitis sicca, pruritus, dry skin.
View ADR Monitoring Form |
|
Drug Interactions |
Potent CYP3A4 or combined CYP3A4/CYP1A2 inhibitors or inducers, drugs that alter gastric pH or reduce gastric acid production, warfarin, other coumarin derivative anticoagulants.
View more drug interactions with Tarceva |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Description |
View Tarceva description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Tarceva mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
